Mereo BioPharma Advances Alvelestat Toward Phase 3 Trial
LONDON, UK; SOLANA BEACH, California; and AHMEDABAD, India, August 11, 2026 Mereo BioPharma Group plc and Sentynl Therapeutics, Inc.,...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
LONDON, UK; SOLANA BEACH, California; and AHMEDABAD, India, August 11, 2026 Mereo BioPharma Group plc and Sentynl Therapeutics, Inc.,...
TARRYTOWN, N.Y., May 18, 2026 Regeneron Pharmaceuticals has announced a major strategic collaboration with Parabilis Medicines valued at up...
PARIS, France, May 18, 2026 Sanofi has announced positive Phase 2 ElevAATe trial results demonstrating that investigational therapy efdoralprin...
CAMBRIDGE, Mass., May 12, 2026 AIRNA announced new preclinical findings at the 2026 American Society of Gene and Cell...
Basel, Switzerland, December 2, 2025 —Roche has announced the launch of a rapid 15-minute point-of-care PCR test capable of...
Tarrytown, New York & Somerville, Massachusetts, December 1, 2025 — Regeneron and Tessera Therapeutics have announced a global collaboration...
